Nanora Bioscience Corporation, based in California, is at the forefront of developing, manufacturing, and commercializing innovative siRNA-based cancer therapeutics. Our mission is to leverage cutting-edge technology to target cancer cells, aiming to inhibit
tumor growth and transform cancer treatment with patient-focused solutions.
Our initial clinical focus is on Head and Neck Cancer (Squamous Cell Carcinoma), with a groundbreaking human trial on the horizon. This formulation employs a biodegradable, efficient, and uniquely designed delivery system targeting the PLK1 gene, a critical factor in cancer cell survival. Derived from chitosan, a natural compound sourced from shrimp shells, our advanced hydrogel-based system offers a safer and more precise alternative to conventional lipid-based carriers.
To enhance quality of life by developing innovative, effective, and safe pharmaceutical
solutions. We strive to:
At Nanora Bioscience Corporation, we stand at the intersection of science and technology, pioneering novel therapeutic solutions with a legacy of innovation. Our Leadership in nano-delivery systems ensures we remain at the forefront of pharmaceutical advancements.
“Disclaimer:
This website is intended exclusively for accredited investors who have been directly contacted by our team. The information provided on this site is speculative and forward-thinking, reflecting our vision for the future once Nora HNC 1000 is approved. At present, the products and statements discussed have not been clinically tested or approved by the U.S. Food and Drug Administration (FDA) or any other regulatory body. This site is not a solicitation for investment, and access is restricted to those who have been invited to view
Nanora Bioscience Corporation, based in California, is at the forefront of developing, manufacturing, and commercializing innovative siRNA-based cancer therapeutics. Our mission is to leverage cutting-edge technology to target cancer cells, aiming to inhibit tumor growth and transform cancer treatment with patient-focused solutions.
